Can Mounjaro Give You Constipation?

What the trial data recorded about Mounjaro and bowel changes

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed more than 2,500 adults over 72 weeks and captured a detailed picture of side effects at each tirzepatide dose. Gastrointestinal reactions were the most frequently reported category. Constipation appeared consistently across the treatment arms, with incidence rising slightly at higher doses. It was classified as mild to moderate in the majority of participants and rarely led to discontinuation of treatment.

The mechanism is well understood. Tirzepatide activates both the GLP-1 and GIP receptors, which slows gastric emptying. Food moves more slowly from the stomach into the small intestine, and that delay ripples through the rest of the digestive system. For some people this means softer, less frequent stools — commonly reported as nausea or diarrhoea early on — but for others the effect tips the other way and constipation follows. If you want to understand exactly why this happens, our page exploring whether Mounjaro causes constipation walks through the receptor-level detail in plain language. Which side of that balance any individual lands on is hard to predict in advance, which is one reason side effects are discussed at consultation rather than after the pen arrives.

You can read the full side-effect profile on the NHS tirzepatide medicines page, which covers both common and rare reactions in plain language. Our own overview of Mounjaro side effects puts the gastrointestinal picture in context alongside the wider tolerability data.

When constipation on Mounjaro typically peaks, and when to get medical help

For most people, gut-related side effects are front-loaded. The first four weeks of treatment and the days following each dose increase are the periods when the body is adapting most actively. Constipation that appears at this point, is manageable and resolves within a couple of weeks, fits the expected pattern. It does not usually signal that treatment needs to stop.

There are, however, symptoms that require prompt medical assessment rather than watchful waiting. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines highlighted acute pancreatitis as an infrequent but serious risk: the warning sign is severe, persistent stomach pain that radiates to the back, with or without vomiting. This is distinct from ordinary constipation discomfort and should not be managed at home. Signs of significant dehydration (dizziness, very dark urine, inability to keep fluids down due to vomiting) also warrant contacting a clinician or calling 111. Gallbladder problems, another recognised risk with this class of medicine, can present as pain in the upper right abdomen that may be severe. If in doubt, seek advice rather than wait. The MHRA Yellow Card scheme allows patients to report suspected side effects and contributes to ongoing safety monitoring of tirzepatide. Reporting even mild but persistent reactions helps build the national picture.

If you are already on treatment and unsure whether what you are experiencing is typical, our aftercare team is available seven days a week.

Practical steps that may help, and what the Patient Information Leaflet says

Constipation on Mounjaro is not simply a nuisance to tolerate. There are straightforward things worth trying, though the definitive source for personalised guidance is your prescriber and the Patient Information Leaflet supplied with your pen.

Fluid intake is usually the first thing to address. The same appetite suppression that makes Mounjaro effective can mean people forget to drink enough through the day, easy to overlook when you are no longer hunger-cued to visit the kitchen. Dietary fibre matters too: vegetables, pulses, oats and fruit all support regular bowel movement, and these foods tend to align well with the lower-calorie eating pattern recommended alongside treatment anyway.

Gentle movement helps some people. A daily walk, even a short one, can encourage gut motility without adding pressure on a system already adjusting to a new medicine. Some patients find that the constipation resolves naturally once the body settles at a given dose, only to return briefly after the next step up. Our page on how and why Mounjaro causes constipation explains that pattern in more detail, which many people find makes it easier to manage without alarm.

For a structured look at what helps, our guide to managing constipation on Mounjaro covers the practical detail. The broader Mounjaro and constipation topic page also addresses the most common questions people bring to our prescribers. If you have not yet started treatment, the Mounjaro overview explains how the medicine works from the beginning.

How this comes up in the consultation, and what our prescribers look for

A Mounjaro consultation at nume is reviewed by a GPhC-registered Independent Prescriber, not a form-processing system. Side-effect history matters to that assessment. Someone with a history of slow bowel motility, irritable bowel syndrome with a constipation-dominant pattern, or significant diverticular disease will have a different conversation than someone with none of those factors. Neither group is automatically excluded, but the discussion is different and the monitoring plan may differ too.

People already on Mounjaro through another provider and transferring to us are asked to provide evidence of their current dose and any side effects they have experienced. That history shapes the clinical review. If constipation has been a significant problem, there are things a prescriber can suggest or monitor more closely, approaches that are specific to the individual rather than generic advice.

Our clinical team takes the view that understanding likely side effects before the first pen arrives is part of safe prescribing, not an afterthought. You can learn more about how we approach clinical oversight on our about us page. When you are ready to discuss whether Mounjaro is suitable for you, check your eligibility to start a free consultation.